Online citations, reference lists, and bibliographies.

Mesothelioma: An Evidence-Based Review

Julie Goudreault, Anne Dagnault
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The initial discovery of mesothelioma can be traced back to 1767 when Dr. Joseph Lieutaud, an anatomy pathologist in France, first identified a tumour in the chest wall of a young boy [1]. Mesothelioma is a rare, aggressive form of cancer that develops from transformed cells originating in the mesothelium, which is the protective lining covering many of the body's internal organs. Mesothelioma arises in the pleura but also occurs in the peritoneum, the tunica vaginalis, and the pericardium [2]. Mesothelioma tends to have a local progression. While disseminated disease has sometimes been reported in a very late stage of the disease [3– 7], patients usually die from local progression.
This paper references
10.1016/S0025-6196(12)65411-1
Malignant mesothelioma of the pleura.
R. J. Pisani (1988)
10.1378/chest.107.6_Supplement.332S
Current approach to malignant mesothelioma of the pleura.
J. Aisner (1995)
10.2131/JTS.33.105
Induction of mesothelioma in p53+/- mouse by intraperitoneal application of multi-wall carbon nanotube.
A. Takagi (2008)
10.1097/01.MP.0000056981.16578.C3
Value of Mesothelin Immunostaining in the Diagnosis of Mesothelioma
N. Ordóñez (2003)
10.1093/JNCI/DJI278
Second cancers among 40,576 testicular cancer patients: focus on long-term survivors.
L. Travis (2005)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1200/JCO.1999.17.1.25
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
10.1016/0007-0971(83)90068-2
Malignant mesothelioma 1982: review of 4710 published cases.
G. Hillerdal (1983)
10.1016/0360-3016(82)90379-0
Radiation therapy in the management of patients with mesothelioma.
W. Gordon (1980)
adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma
W Weder (2004)
10.1093/ANNONC/MDL345
Epidemiology of peritoneal mesothelioma: a review.
P. Boffetta (2007)
10.1201/b10448-105
Computed Tomography, Positron Emission Tomography, and Magnetic Resonance Imaging
Todd Pawlicki (2010)
10.2214/AJR.172.4.10587144
Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.
R. Heelan (1999)
Environmental asbestos exposure and malignant pleural mesothelioma : Special Issue Featuring Chronic Bronchitis and Chronic Obstructive Pulmonary Disease: Finnish National Guidelines for Prevention and Treatment 1998-2007
Muzaffer Metintas (1999)
10.1093/ANNONC/MDM501
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
B. Castagneto (2008)
10.1200/JCO.2003.06.122
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
G. Scagliotti (2003)
10.1016/J.IJROBP.2007.03.011
Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma.
D. Rice (2007)
10.1371/journal.pone.0018828
Losses of Both Products of the Cdkn2a/Arf Locus Contribute to Asbestos-Induced Mesothelioma Development and Cooperate to Accelerate Tumorigenesis
D. Altomare (2011)
10.1016/S0272-5231(05)70076-9
CT and MR in pleural disease.
T. Mcloud (1998)
10.1016/S0022-5223(19)36577-8
The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.
V. Rusch (1991)
10.1097/JTO.0b013e3181c0a7ff
Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related Benign Pleural Disease: An Observational Pilot Study
H. Yildirim (2009)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.2214/ajr.151.5.883
High-resolution CT of benign asbestos-related diseases: clinical and radiographic correlation.
D. Aberle (1988)
10.1097/00000478-199203000-00006
Monoclonal Antibody K1 Reacts With Epithelial Mesothelioma but not With Lung Adenocarcinoma
K. Chang (1992)
10.1016/J.ATHORACSUR.2007.04.076
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.
D. Rice (2007)
10.1152/ajplung.1995.268.3.L471
Asbestos causes DNA strand breaks in cultured pulmonary epithelial cells: role of iron-catalyzed free radicals.
D. Kamp (1995)
10.1016/S0169-5002(02)00180-0
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
T. Berghmans (2002)
10.1200/JCO.2006.09.7634
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
L. Garland (2007)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.3816/CLC.2009.n.033
Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma.
Brad E Wilcox (2009)
Malignant mesothelioma: Advances in pathogenesis, diagnosis, and translational therapies
HI Pass (2005)
10.1200/JCO.2011.39.6671
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
10.1038/ng.912
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
10.1016/S0169-5002(03)92473-1
P-506 Gemcitabine combined to carboplatin in malignant pleural mesothelioma: a multicentric phase II study
A. Favaretto (2003)
10.1016/j.lungcan.2012.05.111
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
Jonathan E. Dowell (2012)
Malignant pleural mesothelioma: Evaluation with CT, MR imaging, and PET. Radio‐ graphics 2004;24(1):105-19
ZJ Wang (2004)
10.1080/10937404.2011.556047
Pulmonary Endpoints (Lung Carcinomas and Asbestosis) Following Inhalation Exposure to Asbestos
B. Mossman (2011)
10.1016/0360-3016(91)90054-8
Deterioration in lung function following hemithorax irradiation for pleural mesothelioma.
P. Maasilta (1991)
10.1136/thx.31.1.15
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
10.1016/j.ejcts.2008.07.050
Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy.
J. Sørensen (2008)
10.1038/nm0897-913
The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas
A. Luca (1997)
vention , early detection , and management of complications after 328 consecutive ex ‐ trapleural pneumonectomies
DJ Sugarbaker (2004)
ithoracic radiation after extrapleural pneumonectomy for malignant pleural meso ‐ thelioma
S Yajnik (2003)
10.2214/ajr.137.2.287
CT of malignant pleural mesothelioma.
E. Alexander (1981)
10.1016/0360-3016(84)90050-6
Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma.
B. Hilaris (1984)
10.1097/00130404-200311000-00008
Promising Early Local Control of Malignant Pleural Mesothelioma Following Postoperative Intensity Modulated Radiotherapy (IMRT) to the Chest
A. Ahamad (2003)
10.1016/j.lungcan.2009.06.014
Prophylactic radiotherapy to intervention sites in mesothelioma: a systematic review and survey of UK practice.
C. Lee (2009)
10.1378/chest.103.4_Supplement.382S
Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma.
V. Rusch (1993)
10.1016/J.RADONC.2007.05.022
A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.
N. O’Rourke (2007)
10.1016/S0360-3016(03)00287-6
Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma.
S. Yajnik (2003)
10.1200/JCO.2004.10.071
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2004)
10.1097/00004728-198308000-00009
Computed tomography of malignant pleural mesothelioma.
D. Grant (1983)
10.1053/SONC.2002.30228
The role of imaging in malignant pleural mesothelioma.
E. Marom (2002)
10.1053/SONC.2002.30227
The pathogenesis of mesothelioma.
M. Carbone (2002)
10.1007/S002680020021
Treatment of Malignant Mesothelioma
M. Jaklitsch (2001)
Trimodality thera‐ py with induction chemotherapy followed by extrapleural pneumonectomy and ad‐ juvant high-dose hemithoracic radiation for malignant pleural mesothelioma
M De Perrot (2009)
10.1183/09031936.99.14613819
Detection of SV40 like viral DNA and viral antigens in malignant pleural mesothelioma.
M. Ramael (1999)
10.1016/S0003-4975(96)01228-3
Patterns of failure after trimodality therapy for malignant pleural mesothelioma.
E. Baldini (1997)
10.1159/000056289
Incidence of Malignant Pleural Mesothelioma due to Environmental Asbestos Fiber Exposure in the Southeast of Turkey
A. Şenyiğit (2000)
10.1200/JCO.2008.17.5604
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
10.1016/j.radonc.2011.08.038
Prophylactic irradiation of intervention sites in malignant pleural mesothelioma.
Marie-Anne Froment (2011)
terns of failure after trimodality therapy for malignant pleural mesothelioma
EH Baldini (1997)
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.1016/S0140-6736(08)60727-8
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
M. Muers (2008)
10.1200/JCO.2008.19.8523
Malignant pleural mesothelioma.
A. Tsao (2009)
10.3816/CLC.2003.N.031
Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40.
A. Gazdar (2003)
10.1067/MTC.2002.125817
Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma.
T. T. Lee (2002)
10.1038/nnano.2008.111
Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study.
Craig A. Poland (2008)
10.1093/jnci/78.6.1053
Demographic patterns for mesothelioma in the United States.
R. Connelly (1987)
Behavior of crocidolite asbestos during mitosis in living vertebrate lung epithelial cells.
J. Ault (1995)
10.1378/chest.103.4_Supplement.373S
Natural history and epidemiology of malignant mesothelioma.
K. Antman (1993)
10.1148/RG.241035058
Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET.
Z. Wang (2004)
10.1038/sj.bjc.6602307
The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050
J. Hodgson (2005)
10.1016/j.ejcts.2009.04.044
Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies.
D. Trousse (2009)
10.1038/ng.855
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
Matthew J Bott (2011)
10.1016/S0360-3016(98)00409-X
Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura--a single-institution experience with 189 patients.
L. de Graaf-Strukowska (1999)
CT of malignant pleural mesothelio
E Alexander (1981)
10.1038/sj.bjc.6602240
Cancer mortality in a cohort of asbestos textile workers
E. Pira (2005)
10.1016/j.lungcan.2008.08.014
Functional inactivation of NF2/merlin in human mesothelioma.
Claudio Thurneysen (2009)
10.2214/ajr.154.3.2106209
CT in differential diagnosis of diffuse pleural disease.
A. Leung (1990)
10.1016/0360-3016(87)90173-8
Technique for external beam treatment for mesothelioma.
G. Kutcher (1987)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1136/oem.17.4.260
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
J. Wagner (1960)
10.1016/j.athoracsur.2009.12.041
Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile?
Bram Balduyck (2010)
10.1016/0037-198X(92)90053-5
Asbestos-related chest diseases: plain radiographic findings.
W. Miller (1992)
10.1164/RCCM.200412-1731OC
Residential proximity to naturally occurring asbestos and mesothelioma risk in California.
X. Pan (2005)
10.1002/ijc.22006
Interleukin‐6 induces both cell growth and VEGF production in malignant mesotheliomas
Yasuo Adachi (2006)
10.1200/JCO.2007.12.5294
Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
A. Bottomley (2007)
10.1378/chest.108.3.754
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
10.1111/J.1440-1827.2007.02080.X
Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
K. Kushitani (2007)
10.1016/J.JTCVS.2004.02.021
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.
D. Sugarbaker (2004)
10.1002/1097-0142(19801215)46:12<2736::AID-CNCR2820461233>3.0.CO;2-L
Latency of asbestos disease among insulation workers in the United States and Canada
I. Selikoff (1980)
10.1002/cncr.22526
Therapeutic radiation for lymphoma
M. J. Teta (2007)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Cigarette smoking, asbestos exposure, and malignant mesothelioma.
J. Muscat (1991)
10.1378/CHEST.122.6.2224
Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area.
S. Metintaş (2002)
10.1016/S0022-5223(98)00438-3
Human mesotheliomas contain the simian virus-40 regulatory region and large tumor antigen DNA sequences.
H. Pass (1998)
10.1016/0169-5002(96)81623-0
Environmental exposure to crocidolite and mesothelioma: exposure-response relationships.
J. Hansen (1996)
10.1159/000056290
Malignant Pleural Mesothelioma Caused by Environmental Exposure to Asbestos in the Southeast of Turkey: CT Findings in 117 Patients
A. Şenyiğit (2000)
10.1016/S0954-6111(99)90318-9
Environmental asbestos exposure and malignant pleural mesothelioma.
M. Metintas (1999)
10.1111/J.1445-5994.2000.TB02050.X
Simian virus (SV) 40 like sequences in cell lines and tumour biopsies from Australian malignant mesotheliomas.
B. Mclaren (2000)
10.1164/AJRCCM.157.1.96-11086
Enviromental exposure to crocidolite and mesothelioma: Exposure-response relationships
J. Hansen (1995)
10.1378/CHEST.114.3.713
Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography.
F. Bénard (1998)
10.1158/1078-0432.CCR-06-2144
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
10.1016/j.ijrobp.2007.11.011
Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience.
E. Miles (2008)
comes after extrapleural pneumonectomy and intensity - modulated radiation therapy for malignant pleural mesothelioma
DC Rice (2007)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1002/cncr.11405
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma
A. Favaretto (2003)
10.1002/cncr.21971
The risk of secondary malignancies over 30 years after the treatment of non‐Hodgkin lymphoma
J. Tward (2006)
10.1016/S0360-3016(02)04150-0
Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation.
K. Forster (2003)
10.1016/j.ijrobp.2009.06.037
Radiotherapy in malignant pleural mesothelioma.
M. McAleer (2009)



Semantic Scholar Logo Some data provided by SemanticScholar